
本網站中所有資料(包括圖檔及文字檔),著作權皆屬本會所有(除另有註明者,或本會網站連結至外部之網站除外),如有引用,請確實註明出處來源。<完整資訊>
©Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
地址:115 台北市南港區園區街3號16樓之1
電話:(02)2655-8168
傳真:(02)2655-7978

2022年生醫(含農業科技類)上市櫃(含興櫃)共211家企業,總營收累計至6月底為1617.5億元,相較2021年同期共195家為1567億元,成長3.2%。
2022年Q2總營收為848.9億元,相較2021年同期758.2億元,成長12%。
2022年H1相較2021年同期營收成長率前3類別依序為「生技服務/基因檢測服務」(29.2%)、「醫材製造/研發」(7.8%)、及「藥品製造/新藥研發」(7.1%)。
行業別 | 2022年H1(Q1+Q2) | 2021年H1(Q1+Q2) | 2022年H1 營收總成長率(%) |
||||
---|---|---|---|---|---|---|---|
總營收(億) | 家數 | 平均營收(億) | 總營收(億) | 家數 | 平均營收(億) | ||
藥品製造/新藥研發 | 396.9 | 72 | 5.5 | 370.7 | 67 | 5.5 | 7.1% |
醫材製造/研發 | 371.8 | 64 | 5.8 | 344.8 | 55 | 6.3 | 7.8% |
健康器材及預防保健品 | 299.6 | 18 | 16.6 | 344.3 | 18 | 19.1 | -13% |
醫療通路/產品經銷 | 276.2 | 15 | 18.4 | 207.7 | 14 | 14.8 | 33% |
醫學美容/藥妝保健 | 104.5 | 11 | 9.5 | 109.5 | 12 | 9.1 | -4.6% |
農業生技/農科健康 | 71.4 | 9 | 7.9 | 100.1 | 10 | 10 | -28.7% |
原料藥 | 59.9 | 7 | 8.6 | 61.1 | 7 | 8.7 | -2% |
生技服務/基因檢測服務 | 37.2 | 15 | 2.5 | 28.8 | 12 | 2.4 | 29.2% |
總計 | 1617.5 | 211 | 74.8 | 1567 | 195 | 76 | 3.2% |
排名 | 公司名稱 (代號) |
營收-億元(同期成長率%) | ||
---|---|---|---|---|
2022Q1 | 2022Q2 | 2022Q1+Q2 | ||
1 | 喬山(1736) | 75.2(3.7%) | 65.5(-0.6%) | 140.7(1.7%) |
2 | 大樹(6469) | 32(28.6%) | 39.7(40.8%) | 71.7(35.1%) |
3 | 美時(1795) | 31.6(-4.9%) | 29.1(-16%) | 60.7(-10.6%) |
4 | 泰博(4736) | 17.9(33.1%) | 36.3(116.2%) | 54.2(79.2%) |
5 | 葡萄王(1707) | 20.5(4.1%) | 27.2(8.7%) | 47.8(6.7%) |
6 | 中化(1701) | 19.5(-2.9%) | 20.9(2.1%) | 40.4(-0.4%) |
7 | 永信(3705) | 19.5(9.9%) | 19.6(1.9%) | 39.1(5.7%) |
8 | 杏一(4175) | 16.1(7.6%) | 20.5(21.3%) | 36.5(14.9%) |
9 | 岱宇(1598) | 22.6(-41%) | 13.8(-50.5%) | 36.4(-45%) |
10 | 大江(8436) | 16.6(-14.8%) | 18.5(-20.9%) | 35.1(-18.1%) |
11 | 佳醫(4104) | 17.1(5%) | 16.7(5.8%) | 33.8(5.4%) |
12 | 晶碩(6491) | 14.9(29.9%) | 14.1(2.4%) | 29(14.9%) |
13 | 合富-KY(4745) | 13.6(21.8%) | 14(-5.6%) | 27.5(6.2%) |
14 | 杏昌(1788) | 9.8(11.3%) | 17.6(76.2%) | 27.4(45.8%) |
15 | 生達(1720) | 12.4(12.4%) | 14.8(28.9%) | 27.2(20.8%) |
16 | 精華(1565) | 13.5(3%) | 12.3(-8.8%) | 25.7(-2.9%) |
17 | 保瑞(6472) | 11.2(-18.2%) | 13.5(12.2%) | 24.7(-3.9%) |
18 | 友華(4120) | 11.4(-5.9%) | 12(6.3%) | 23.5(0%) |
19 | 諾貝兒(6844) | 9.7(6.9%) | 12.6(27.1%) | 22.3(17.4%) |
20 | 優盛(4121) | 9.1(-4.2%) | 12.9(25.8%) | 22.1(11.4%) |
排名 | 上市公司 (代號) |
營收-億元(同期成長率%) | ||
---|---|---|---|---|
2022Q1 | 2022Q2 | 2022Q1+Q2 | ||
1 | 喬山(1736) | 75.2(3.7%) | 65.5(-0.6%) | 140.7(1.7%) |
2 | 美時(1795) | 31.6(-4.9%) | 29.1(-16%) | 60.7(-10.6%) |
3 | 葡萄王(1707) | 20.5(4.1%) | 27.2(8.7%) | 47.8(6.7%) |
4 | 中化(1701) | 19.5(-2.9%) | 20.9(2.1%) | 40.4(-0.4%) |
5 | 永信(3705) | 19.5(9.9%) | 19.6(1.9%) | 39.1(5.7%) |
6 | 岱宇(1598) | 22.6(-41%) | 13.8(-50.5%) | 36.4(-45%) |
7 | 佳醫(4104) | 17.1(5%) | 16.7(5.8%) | 33.8(5.4%) |
8 | 晶碩(6491) | 14.9(29.9%) | 14.1(2.4%) | 29(14.9%) |
9 | 生達(1720) | 12.4(12.4%) | 14.8(28.9%) | 27.2(20.8%) |
10 | 麗豐-KY(4137) | 10.3(-6.8%) | 7.6(-39.6%) | 18(-24.3%) |
11 | 台耀(4746) | 8.3(13.4%) | 8.4(0.6%) | 16.7(6.6%) |
12 | 全宇生技-KY(4148) | 6.7(63%) | 9.2(63.5%) | 15.9(63.3%) |
13 | 神隆(1789) | 7.4(15.1%) | 8.1(7.7%) | 15.4(11.1%) |
14 | 杏輝(1734) | 6.7(8.3%) | 7.1(17.8%) | 13.8(13%) |
15 | 承業醫(4164) | 6.1(-5.4%) | 6.9(56.3%) | 13(19.8%) |
16 | 佐登-KY(4190) | 6.4(-12.6%) | 6.6(-2.9%) | 12.9(-8%) |
17 | 雃博(4106) | 6(2.5%) | 6.8(18%) | 12.8(10.2%) |
18 | 寶齡富錦(1760) | 4.5(21.5%) | 8.1(52.8%) | 12.7(39.9%) |
19 | 五鼎(1733) | 5.2(-9.4%) | 6.1(25.5%) | 11.3(6.5%) |
20 | 中化生(1762) | 5.3(25.6%) | 5.8(15.9%) | 11.1(20.3%) |
排名 | 上櫃公司 (代號) |
營收-億元(同期成長率%) | ||
---|---|---|---|---|
2022Q1 | 2022Q2 | 2022Q1+Q2 | ||
1 | 大樹(6469) | 32(28.6%) | 39.7(40.8%) | 71.7(35.1%) |
2 | 泰博(4736) | 17.9(33.1%) | 36.3(116.2%) | 54.2(79.2%) |
3 | 杏一(4175) | 16.1(7.6%) | 20.5(21.3%) | 36.5(14.9%) |
4 | 大江(8436) | 16.6(-14.8%) | 18.5(-20.9%) | 35.1(-18.1%) |
5 | 合富-KY(4745) | 13.6(21.8%) | 14(-5.6%) | 27.5(6.2%) |
6 | 杏昌(1788) | 9.8(11.3%) | 17.6(76.2%) | 27.4(45.8%) |
7 | 精華(1565) | 13.5(3%) | 12.3(-8.8%) | 25.7(-2.9%) |
8 | 保瑞(6472) | 11.2(-18.2%) | 13.5(12.2%) | 24.7(-3.9%) |
9 | 友華(4120) | 11.4(-5.9%) | 12(6.3%) | 23.5(0%) |
10 | 優盛(4121) | 9.1(-4.2%) | 12.9(25.8%) | 22.1(11.4%) |
11 | 東洋(4105) | 10.4(7.6%) | 11.6(11.7%) | 22(9.7%) |
12 | 盛弘(8403) | 10.4(15.6%) | 11.2(18.4%) | 21.6(17%) |
13 | 健喬(4114) | 9.7(26.6%) | 10.6(36%) | 20.3(31.4%) |
14 | 茂生農經(1240) | 7.6(18%) | 8.8(19.1%) | 16.4(18.6%) |
15 | 大學光(3218) | 8.4(36.9%) | 7.9(28.4%) | 16.2(32.6%) |
16 | 寶島科(5312) | 8.2(4.4%) | 7.2(20.6%) | 15.4(11.4%) |
17 | 聯合(4129) | 7.4(18.1%) | 7.6(27.4%) | 15(22.6%) |
18 | 惠光(6508) | 6.3(20.4%) | 7.9(41%) | 14.3(31.1%) |
19 | 明基醫(4116) | 6.2(85.5%) | 8(137.7%) | 14.2(111.8%) |
20 | 藥華藥(6446) | 2.5(157.7%) | 9.8(1026.9%) | 12.3(566.6%) |
排名 | 興櫃公司 (代號) |
營收-億元(同期成長率%) | ||
---|---|---|---|---|
2022Q1 | 2022Q2 | 2022Q1+Q2 | ||
1 | 諾貝兒(6844) | 9.7(6.9%) | 12.6(27.1%) | 22.3(17.4%) |
2 | 視陽(6782) | 6.5(42.1%) | 7.3(75.5%) | 13.8(58.1%) |
3 | 正瀚(6534) | 5.9(61.8%) | 7(127.5%) | 12.9(91.8%) |
4 | 圓點奈米(6797) | 7.4(-2.6%) | 3.2(-8.3%) | 10.7(-4.4%) |
5 | 睿生光電(6861) | 4.7(-11.7%) | 4.6(-8.4%) | 9.3(-10.1%) |
6 | 麗彤(6539) | 4.9(-1.5%) | 4.3(11.2%) | 9.2(4.1%) |
7 | 康聯生醫(6665) | 3.5(28.7%) | 4.8(54.7%) | 8.3(42.7%) |
8 | 望隼(4771) | 3.6(13.4%) | 4(13.3%) | 7.7(13.4%) |
9 | 太和-KY(4136) | 1.4(-14.9%) | 3(39.8%) | 4.4(15.5%) |
10 | 康科特(6518) | 2(10%) | 2.5(37.3%) | 4.4(23.8%) |
11 | 金萬林(6645) | 1.2(44.6%) | 3.1(89%) | 4.3(73.8%) |
12 | 優你康(4150) | 2.2(-8.6%) | 2(-2.3%) | 4.2(-5.7%) |
13 | 瑩碩生技(6677) | 1.8(-5.2%) | 1.9(-9.5%) | 3.7(-7.5%) |
14 | 泰宗(4169) | 1.7(0.8%) | 2(9.3%) | 3.7(5.2%) |
15 | 立弘(1780) | 1.6(-9.6%) | 2(11.8%) | 3.6(1.1%) |
16 | 普惠醫工(6543) | 1.6(-25.6%) | 1.7(-17.9%) | 3.3(-21.7%) |
17 | 聯亞藥(6562) | 1.5(22.4%) | 1.7(9%) | 3.2(15%) |
18 | 安美得(7575) | 1.5(15.7%) | 1.6(22.9%) | 3.1(19.2%) |
19 | 友霖(4166) | 1.2(32.9%) | 1.8(88.9%) | 3(62.1%) |
20 | 溫士頓(6817) | 1.3(-13.8%) | 1.5(1.8%) | 2.9(-6%) |
資料來源:公開資訊觀測站、生策會/生策中心彙整